| Accurate strategy of antiplatelet drugs in patients with cerebral infarction |
| Received:November 26, 2021 Revised:January 17, 2022 Click here to download the full text |
| Citation of this paper:MA Yu,WU Xu-qing,BI Xiao-ying,DING Su-ju,HAO Zi-long,WU Bo,FAN Wei.Accurate strategy of antiplatelet drugs in patients with cerebral infarction[J].Chinese Journal of Clinical Medicine,2022,29(6):899-905 |
| Hits: 1438 |
| Download times: 360 |
| Author Name | Affiliation | E-mail | | MA Yu | Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WU Xu-qing | Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | BI Xiao-ying | Department of Neurology, Changhai Hospital, Naval Medical University, Shanghai 200433, China | | | DING Su-ju | Department of Neurology, Changhai Hospital, Naval Medical University, Shanghai 200433, China | | | HAO Zi-long | Department of Neurology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China | | | WU Bo | Department of Neurology, West China Hospital of Sichuan University, Chengdu 610041, Sichuan, China | | | FAN Wei | Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | Fan.Wei@zs-hospital.sh.cn |
|
| Abstract:Antiplatelet therapy is a major component of the management of cerebral infarction. However, there are differences in individual responses to antiplatelet drugs which are closely related to the clinical prognosis. Therefore, accurate selection of antiplatelet drugs is of great significance. Platelet function and genetic testing are core elements of precision treatment with antiplatelet drugs. For patients with high risk of ischemic event, poor prognosis or bleeding, genetic testing and/or platelet function testing may be considered. Aspirin and clopidogrel are currently classic antiplatelet drugs, and the effectiveness and safety of other antiplatelet drugs need to be further verified. For patients who are resistant to aspirin, it is recommended to consider switching to other antiplatelet drugs rather than to increase the dose of aspirin. The strategy of clopidogrel dose adjustment based on CYP2C19 genotype remains to be studied. Patients carrying CYP2C19 loss-of-function alleles are recommended to switch to other antiplatelet drugs. |
| keywords:cerebral infarction antiplatelet drug accurate strategy genetic testing |
| HTML View Full Text View/Add Comment Download reader |
|
|
|